Whilst the clinical development of those agents is still too preliminary forany definitive conclusions to be drawn, early data from phase I clinical trials do notsupport a strong association of anti-tumor activity by pan-class I PI3K blocking agentswith PIK3CA genotype [72-74]. Here, PIK3CA is linked to neoplasm.